Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Alliance raises concerns over new health insurance extras

National Rural Health Alliance 2 mins read

The National Rural Health Alliance (the Alliance) voices concern over new extras offered by some of Australia’s biggest health insurers with the claim that they will be an offset to high premiums.

 

A major private health insurer is now trialling a new scheme offering three free virtual General Practitioner (GP) visits each year with extras cover. Other health insurance companies are exploring similar “perks”. Such new offers need special approval from the Department of Health and Aged Care, as private insurers are currently prohibited from out-of-hospital medical services like GP visits and certain diagnostic testing.  

 

“While this might appear beneficial for consumers in reducing the cost-of-living crisis, a reduction in private health premiums and increased support on out-of-pocket costs is much more meaningful. Primary care is not the core business of private health insurers. Entering the primary care part of the health system without collaboration or being part of the existing primary care team can exacerbate the healthcare accessibility challenges already prevalent in rural, regional and remote communities,” said the Alliance Chief Executive Susi Tegen.

 

“The remit for private insurers is to fund tertiary, secondary and extras care and do so generously and equitably, rather than expand into primary care. Patients deserve holistic care with their multidisciplinary primary care providers, who know the patient's journey rather than confuse the patient and care providers.

 

“Expansion into primary care could also detract from vital government support for local services in rural and remote areas that need continuous funding. While virtual GP consultations may partly suffice for certain health issues, they cannot replace face-to-face health care. It can also potentially impact the continuity of care.

 

“Rates of private health insurance coverage reduce with remoteness. So, it would be much more helpful if the private health insurance industry provided more support and equity to those who are covered under private health insurance, but are not able to access the full complement of services and rebates purely, due to their postcode,” Ms Tegen said.

 

The Alliance urges the government to reassess these developments concerning primary healthcare funding of services and ensure that rural communities and their clinicians are supported to provide services and are not left out in the healthcare equation.


About us:

The National Rural Health Alliance (the Alliance) comprises 52 national organisations committed to improving the health and wellbeing of the over 7 million people in rural and remote Australia. Our diverse membership includes representation from the Aboriginal and Torres Strait Islander health sector, health professional organisations, health service providers, health educators and students.


Contact details:

Kathya de Silva, Media and Communications Officer, National Rural Health Alliance,

media@ruralhealth.org.au 0470 487 608 

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.